An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug 

As if the saga of aducanumab needed another twist, the Food and Drug Administration tossed in an extra curveball Monday as it approved the Alzheimer’s therapy by specifying for which patients the therapy was authorized.

Or rather, not specifying.

Read the rest…